Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026, the Compensation Committee of Recursion's Board of ...

Learn how Zero-Knowledge Proofs (ZKP) provide verifiable tool execution for Model Context Protocol (MCP) in a post-quantum world. Secure your AI infrastructure today.

Kevin Cann’s "Platonic Surrealism" hits #1 on Amazon, bridging Neoplatonism and UAP phenomena with a practical ...

Why write ten lines of code when one will do? From magic variable swaps to high-speed data counting, these Python snippets ...

A marriage of formal methods and LLMs seeks to harness the strengths of both.

OpenAI's GPT-5.2 derived a new formula for gluon interactions, overturning assumptions of zero amplitude and advancing ...

OpenAI’s GPT-5.2 collaborated with leading physicists to derive and formally prove new results on gluon scattering amplitudes ...

Welp, here's another NUC (Next Unit of Computing) to fill your list of absurdly small PCs. This time, we get to review the ASUS NUC 15 Pro+, another small ...

Corey Schafer’s YouTube channel is a go-to for clear, in-depth video tutorials covering a wide range of Python topics. The ...

The ChatGPT maker says the Chinese firm may be distilling its models, underscoring rising tech tensions between Washington and Beijing.

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...